DIP Ep 670: USMLE Pharm Crash Course, The Drugs That Matter (Part 1)
Topic
Cardiovascular & Renal Pharmacology; ACE Inhibitors & ARBs; Beta-Blockers (selective vs non-selective vs alpha/beta); Calcium Channel Blockers (Dihydropyridines vs Non-dihydropyridines); Diuretics (Loop, Thiazide, Potassium-sparing, Carbonic anhydrase inhibitors); Statins & Lipid-lowering agents.
Key Takeaway
Mastering cardiovascular and renal pharmacology requires linking drug mechanisms directly to hemodynamic shifts, electrolyte disturbances, and mortality benefits. ACEi/ARBs, Beta-blockers, and Aldosterone antagonists form the bedrock of mortality reduction in HFrEF, each carrying distinct electrolyte and renovascular caveats.
Episode Notes
Source / episode info
- Episode: 670
- Title: DIP Ep 670: USMLE Pharm Crash Course, The Drugs That Matter (Part 1)
- Published: 2026-09-07
- Source: DIP Ep 670: USMLE Pharm Crash Course, The Drugs That Matter (Part 1)
One-liner
Part 1 of the USMLE/COMLEX Pharmacology Crash Course covers the high-yield cardiovascular and renal drugs: ACE inhibitors, ARBs, Beta-blockers, Calcium channel blockers, all diuretic classes, and statins.
High-yield summary
- Heart Failure Mortality Benefit Medications (Quad Therapy in HFrEF): (1) ACEi / ARB / ARNI (Sacubitril-Valsartan), (2) Evidence-based Beta-Blockers (Carvedilol, Metoprolol Succinate, Bisoprolol), (3) Mineralocorticoid Receptor Antagonists (Spironolactone, Eplerenone), (4) SGLT2 Inhibitors (Empagliflozin, Dapagliflozin). Note: Digoxin and Loop Diuretics improve symptoms and reduce hospitalizations but do NOT reduce mortality.
- ACE Inhibitors vs ARBs: ACEi (Lisinopril, Enalapril) inhibit angiotensin-converting enzyme, preventing Ang I -> Ang II and decreasing bradykinin breakdown. Side effects: dry hacking cough and angioedema (due to bradykinin), hyperkalemia, and acute renal decline in bilateral renal artery stenosis (loss of efferent arteriolar vasoconstriction). ARBs (Losartan, Valsartan) block AT1 receptors without elevating bradykinin (no cough). Both are teratogenic (fetal renal dysgenesis).
- Beta-Blocker Classification: Cardioselective (Beta-1 selective): Atenolol, Betaxolol, Bisoprolol, Esmolol, Metoprolol (letters A through M). Nonselective (Beta-1 and Beta-2): Nadolol, Pindolol, Propranolol, Timolol (letters N through Z). Combined Alpha-1 and Beta: Carvedilol, Labetalol (essential in hypertensive emergencies and aortic dissection because alpha blockade prevents reflex vasoconstriction).
- Calcium Channel Blockers (CCBs): Dihydropyridines (Amlodipine, Nifedipine) act predominantly on vascular smooth muscle -> vasodilation, reflex tachycardia, peripheral pedal edema, and gingival hyperplasia. Non-dihydropyridines (Verapamil, Diltiazem) act on cardiac nodal conduction -> negative inotropy and dromotropy; Verapamil causes constipation and hyperprolactinemia; contraindicated in heart failure with reduced ejection fraction.
- Diuretic Breakdown: Loop diuretics (Furosemide, Bumetanide) block Na+/K+/2Cl- cotransporter in thick ascending limb; "Loops Lose Calcium" (hypocalcemia), hypokalemic metabolic alkalosis, ototoxicity, hyperuricemia. Thiazides (Chlorthalidone, Hydrochlorothiazide) block Na+/Cl- in distal convoluted tubule; "Thiazides Take Calcium" (hypercalcemia); hyperGLUC (hyperGlycemia, hyperLipidemia, hyperUricemia, hyperCalcemia). Potassium-sparing (Spironolactone, Eplerenone, Amiloride, Triamterene) cause hyperkalemia and gynecomastia (spironolactone; eplerenone is selective).
Learning objectives
- Identify which cardiovascular drug classes confer proven mortality reduction in systolic heart failure.
- Predict renal hemodynamic shifts (afferent vs. efferent arteriolar resistance) with NSAIDs vs. ACE inhibitors.
- Select the appropriate beta-blocker based on receptor selectivity, intrinsic sympathomimetic activity, and clinical comorbidity (e.g., asthma, pheochromocytoma, aortic dissection).
- Differentiate the metabolic and electrolyte side effect profiles of loop vs. thiazide vs. potassium-sparing diuretics.
- Manage adverse reactions including ACEi angioedema, statin-induced myopathy, and dihydropyridine pedal edema.
Board exam buzzwords
| Drug / Class | Mechanism of Action | Key Adverse Effect | Board Exam Pearl |
|---|---|---|---|
| Lisinopril (ACEi) | Inhibits Ang I -> Ang II & bradykinin degradation | Dry cough, angioedema, hyperkalemia | Contraindicated in pregnancy (oligohydramnios, skull hypoplasia) and bilateral renal artery stenosis. |
| Carvedilol / Labetalol | Combined alpha-1 and nonselective beta-blocker | Orthostatic hypotension, bradycardia, bronchospasm | Labetalol is first-line in pregnancy hypertension and acute aortic dissection. |
| Amlodipine | Dihydropyridine calcium channel blocker | Peripheral pedal edema (pre-capillary vasodilation) | Pedal edema is NOT responsive to diuretics; responds to adding an ACEi/ARB to dilate efferent venules. |
| Furosemide | Inhibits Na+/K+/2Cl- cotransporter in thick ascending limb | Hypokalemia, hypomagnesemia, ototoxicity | Sulfa drug; use Ethacrynic acid in patients with severe sulfa allergy. |
| Chlorthalidone | Inhibits Na+/Cl- cotransporter in distal convoluted tubule | Hypokalemia, hyponatremia, hyperGLUC | Preferred over HCTZ due to longer half-life and superior cardiovascular outcome data. |
| Spironolactone | Competitive aldosterone receptor antagonist | Hyperkalemia, painful gynecomastia | Switch to Eplerenone if gynecomastia occurs (higher mineralocorticoid selectivity). |
Rapid review table
| Clinical Scenario | First-Line Drug of Choice | Contraindicated Drug |
|---|---|---|
| Aortic Dissection | IV Esmolol / Labetalol (target SBP < 120, HR < 60) | Hydralazine or pure vasodilators (reflex tachycardia worsens shear stress) |
| Heart Failure + Severe Sulfa Allergy with pulmonary edema | Ethacrynic acid | Furosemide, Bumetanide, Torsemide |
| Hypertension in Pregnancy | Labetalol, Methyldopa, Nifedipine, Hydralazine | ACE inhibitors, ARBs, Direct renin inhibitors (Aliskiren) |
| Hypertension in patient with recurrent calcium kidney stones | Thiazide diuretics (Chlorthalidone) | Loop diuretics (increase urine calcium excretion) |
Board-speak -> diagnosis
| Vignette Clue | Target Concept / Diagnosis | Why It Fits |
|---|---|---|
| Vignette Clue | Underlying Pharmacologic Explanation | Correct Action |
| Patient started on lisinopril develops acute rise in creatinine from 1.0 to 2.8 mg/dL within 5 days. | Bilateral renal artery stenosis (renal perfusion dependent on efferent arteriolar vasoconstriction). | Discontinue ACEi immediately; evaluate with renal artery duplex ultrasound. |
| Patient with hypertension develops bilateral lower extremity edema without JVD, orthopnea, or proteinuria. | Amlodipine-induced precapillary arteriolar vasodilation and increased capillary hydrostatic pressure. | Add an ACE inhibitor or ARB to induce postcapillary venular dilation, normalizing hydrostatic pressure. |
| Patient with gout and hypertension experiences recurrent acute podagra flares. | Hydrochlorothiazide-induced hyperuricemia (competes with uric acid for renal tubular secretion). | Switch antihypertensive therapy to Losartan (has intrinsic uricosuric properties). |
Management pearls
- Esmolol is an ultra-short-acting IV beta-blocker (half-life ~9 minutes) metabolized by red blood cell esterases, making it ideal for intraoperative and ICU titrations.
- Digoxin toxicity is precipitated by HYPOKALEMIA because potassium and digoxin compete for the same binding site on the Na+/K+ ATPase pump. Symptoms: anorexia, nausea, yellow-green blurry vision, bidirectional VT. Antidote: Digoxin Fab fragments.
- Statins are taken at bedtime because hepatic HMG-CoA reductase activity and cholesterol synthesis peak during the night (except Atorvastatin and Rosuvastatin, which have long half-lives).
Don't miss
Original transcript with highlights
Original transcript with highlights
All right, welcome. This is Episode 670: "USMLE Pharm Crash Course, The Drugs That Matter (Part 1: Cardiovascular & Renal)." Today we are launching a comprehensive 4-part pharmacology review. Pharmacology is heavily tested across every single board exam, and the questions focus ruthlessly on mechanisms of action, adverse effects, and lethal drug-drug interactions.
Let's start with diuretics. Loop diuretics (Furosemide, Bumetanide, Torsemide): Where do they work? The thick ascending limb of the loop of Henle! They inhibit the Na+/K+/2Cl- cotransporter. What are their adverse effects? "OH DANG" mnemonic: Ototoxicity, Hypokalemia/Hypomagnesemia, Dehydration, Allergy (sulfa), Nephritis (interstitial), and Gout (hyperuricemia). What happens to urinary calcium with loop diuretics? Loops LOSE calcium (hypocalcemia)! Compare that to Thiazide diuretics (HCTZ, Chlorthalidone): They work in the distal convoluted tubule inhibiting the Na+/Cl- cotransporter. Thiazides SAVE calcium (hypercalcemia)! That is why thiazides are excellent for hypertensive patients with osteoporosis or recurrent calcium oxalate kidney stones!
Next, the RAAS axis. ACE inhibitors (Lisinopril, Enalapril): Inhibit ACE, blocking Angiotensin II production and preventing bradykinin breakdown. Why do patients get a dry cough and angioedema? Elevated bradykinin and substance P! ARBs (Losartan, Valsartan) block the AT1 receptor directly and do NOT cause cough or angioedema. Both cause hyperkalemia and are strictly contraindicated in bilateral renal artery stenosis (efferent arteriolar vasodilation causes acute GFR collapse). Aldosterone antagonists (Spironolactone vs Eplerenone): Spironolactone blocks androgen receptors, causing gynecomastia and erectile dysfunction; Eplerenone is more selective and avoids gynecomastia.
Now, antiarrhythmics: Class IA (Quinidine, Procainamide, Disopyramide) prolong AP duration and QT; Class IB (Lidocaine, Mexiletine) shorten AP duration and are best for ischemic ventricular arrhythmias; Class IC (Flecainide, Propafenone) prolong ERP without changing AP duration and are contraindicated in post-MI ischemic heart disease (CAST trial). Class III (Amiodarone, Sotalol, Dofetilide) block K+ channels; remember Amiodarone's classic toxicities: pulmonary fibrosis, thyroid dysfunction (hypo or hyper), corneal deposits, blue-gray skin discoloration, and hepatotoxicity. Check PFTs, TFTs, and LFTs before starting amiodarone!
OMM / COMLEX integration
- Cardiovascular viscerosomatic reflexes: T1–T5 sympathetics. Left-sided T1–T5 hypertonicity correlates with ventricular myocardium; right-sided correlates with supraventricular/nodal tissue.
- Renal viscerosomatic reflexes: T10–T11 sympathetics. Sympathetic stimulation constricts renal arterioles and activates the renin-angiotensin-aldosterone cascade.